Malignant mesothelioma - Revision history

Michael at 14:37, 15 September 2025

2025-09-15T14:37:08Z

← Older revision		Revision as of 14:37, 15 September 2025
Line 30:		Line 30:
	'''Malignant mesothelioma''', also '''mesothelioma''', is a form of [[cancer]]. It arises from the mesothelium.		'''Malignant mesothelioma''', also '''mesothelioma''', is a form of [[cancer]]. It arises from the mesothelium.

	It should '''not''' be confused with ''[[benign multicystic mesothelioma]]'' and ''[[benign papillary mesothelioma]]''.		It should '''not''' be confused with ''[[benign multicystic mesothelioma]]'' and ''[[well-differentiated papillary mesothelial tumour]]'' (previously ''benign papillary mesothelioma'').

	==General==		==General==

Michael: /* IHC */ tweak

2025-09-15T14:12:22Z

IHC: tweak

← Older revision		Revision as of 14:12, 15 September 2025
Line 128:		Line 128:

	Note:		Note:
	*The above are ''not'' very useful in individual cases.		*A simple pankeratin is useful for seeing where epithelial cells are.
	*A simple pankeratin is useful for ~~seening~~ where epithelial cells are.

	Others:		Others:

Michael at 19:53, 18 December 2024

2024-12-18T19:53:43Z

← Older revision		Revision as of 19:53, 18 December 2024
Line 145:		Line 145:
	**D2-40.		**D2-40.
	**[[CK5/6]].		**[[CK5/6]].
			**[[CA-125]].<ref name=pmid9023557>{{cite journal \|authors=Bateman AC, al-Talib RK, Newman T, Williams JH, Herbert A \|title=Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression \|journal=Histopathology \|volume=30 \|issue=1 \|pages=49–56 \|date=January 1997 \|pmid=9023557 \|doi=10.1046/j.1365-2559.1996.d01-562.x \|url=}}</ref>
	*Carcinoma markers:		*Carcinoma markers:
	**CEA (monoclonal and polyclonal).		**CEA (monoclonal and polyclonal).

Michael at 14:25, 9 October 2024

2024-10-09T14:25:29Z

← Older revision		Revision as of 14:25, 9 October 2024
Line 149:		Line 149:
	**[[TTF-1]].		**[[TTF-1]].
	**[[Ber-EP4]].		**[[Ber-EP4]].
	**100% of lung adenocarcinoma versus ~25% of mesotheliomas.<ref>{{cite journal \|authors=Ordóñez NG \|title=Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature \|journal=Am J Clin Pathol \|volume=109 \|issue=1 \|pages=85–9 \|date=January 1998 \|pmid= \|doi=10.1093/ajcp/109.1.85 \|url=}}</ref>		***100% of lung adenocarcinoma versus ~25% of mesotheliomas.<ref>{{cite journal \|authors=Ordóñez NG \|title=Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature \|journal=Am J Clin Pathol \|volume=109 \|issue=1 \|pages=85–9 \|date=January 1998 \|pmid= \|doi=10.1093/ajcp/109.1.85 \|url=}}</ref>
	**MOC-31.		**MOC-31.
	**CD15.		**CD15.

Michael at 14:24, 9 October 2024

2024-10-09T14:24:31Z

← Older revision		Revision as of 14:24, 9 October 2024
Line 149:		Line 149:
	**[[TTF-1]].		**[[TTF-1]].
	**[[Ber-EP4]].		**[[Ber-EP4]].
			**100% of lung adenocarcinoma versus ~25% of mesotheliomas.<ref>{{cite journal \|authors=Ordóñez NG \|title=Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature \|journal=Am J Clin Pathol \|volume=109 \|issue=1 \|pages=85–9 \|date=January 1998 \|pmid= \|doi=10.1093/ajcp/109.1.85 \|url=}}</ref>
	**MOC-31.		**MOC-31.
	**CD15.		**CD15.

Michael at 09:49, 10 September 2024

2024-09-10T09:49:30Z

← Older revision		Revision as of 09:49, 10 September 2024
Line 8:		Line 8:
	\| LMDDx = mesothelial hyperplasia, [[fibrosing pleuritis]], [[adenocarcinoma]] - esp. [[lung adenocarcinoma\|lung]], [[serous carcinoma]]		\| LMDDx = mesothelial hyperplasia, [[fibrosing pleuritis]], [[adenocarcinoma]] - esp. [[lung adenocarcinoma\|lung]], [[serous carcinoma]]
	\| Stains =		\| Stains =
	\| IHC = calretinin +ve, D2-40 +ve, [[CK5/6]] +ve, WT-1 +ve, [[CK7]] +ve, CEA -ve, [[TTF-1]] -ve		\| IHC = calretinin +ve, D2-40 +ve, [[CK5/6]] +ve, WT-1 +ve, [[CK7]] +ve, CEA -ve, [[TTF-1]] -ve, MTAP -ve (pleural mesothelioma), BAP1 -ve
	\| EM =		\| EM =
	\| Molecular = +/-p16 deletion		\| Molecular = +/-p16 deletion

Michael at 09:48, 10 September 2024

2024-09-10T09:48:20Z

← Older revision		Revision as of 09:48, 10 September 2024
Line 130:		Line 130:
	*The above are ''not'' very useful in individual cases.		*The above are ''not'' very useful in individual cases.
	*A simple pankeratin is useful for seening where epithelial cells are.		*A simple pankeratin is useful for seening where epithelial cells are.

			Others:
			*MTAP -ve.<ref name=pmid34465883>{{cite journal \|authors=Dacic S \|title=Pleural mesothelioma classification-update and challenges \|journal=Mod Pathol \|volume=35 \|issue=Suppl 1 \|pages=51–56 \|date=January 2022 \|pmid=34465883 \|doi=10.1038/s41379-021-00895-7 \|url=}}</ref>
			**May not be sensitive and specific for peritoneal mesothelioma.{{fact}}

	===Mesothelioma versus adenocarcinoma===		===Mesothelioma versus adenocarcinoma===
Line 156:		Line 160:
	*[[CD138]] +ve.		*[[CD138]] +ve.
	**Usually -ve in mesothelioma.<ref name=pmid12866374>{{Cite journal \| last1 = Chu \| first1 = PG. \| last2 = Arber \| first2 = DA. \| last3 = Weiss \| first3 = LM. \| title = Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. \| journal = Am J Clin Pathol \| volume = 120 \| issue = 1 \| pages = 64-70 \| month = Jul \| year = 2003 \| doi = 10.1309/48KC-17WA-U69B-TBXQ \| PMID = 12866374 }}</ref>		**Usually -ve in mesothelioma.<ref name=pmid12866374>{{Cite journal \| last1 = Chu \| first1 = PG. \| last2 = Arber \| first2 = DA. \| last3 = Weiss \| first3 = LM. \| title = Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. \| journal = Am J Clin Pathol \| volume = 120 \| issue = 1 \| pages = 64-70 \| month = Jul \| year = 2003 \| doi = 10.1309/48KC-17WA-U69B-TBXQ \| PMID = 12866374 }}</ref>
	*MTAP -ve.<ref name=pmid34465883>{{cite journal \|authors=Dacic S \|title=Pleural mesothelioma classification-update and challenges \|journal=Mod Pathol \|volume=35 \|issue=Suppl 1 \|pages=51–56 \|date=January 2022 \|pmid=34465883 \|doi=10.1038/s41379-021-00895-7 \|url=}}</ref>
	**May not be sensitive and specific for peritoneal mesothelioma.{{fact}}

	==Molecular==		==Molecular==

Michael at 09:46, 10 September 2024

2024-09-10T09:46:27Z

← Older revision		Revision as of 09:46, 10 September 2024
Line 156:		Line 156:
	*[[CD138]] +ve.		*[[CD138]] +ve.
	**Usually -ve in mesothelioma.<ref name=pmid12866374>{{Cite journal \| last1 = Chu \| first1 = PG. \| last2 = Arber \| first2 = DA. \| last3 = Weiss \| first3 = LM. \| title = Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. \| journal = Am J Clin Pathol \| volume = 120 \| issue = 1 \| pages = 64-70 \| month = Jul \| year = 2003 \| doi = 10.1309/48KC-17WA-U69B-TBXQ \| PMID = 12866374 }}</ref>		**Usually -ve in mesothelioma.<ref name=pmid12866374>{{Cite journal \| last1 = Chu \| first1 = PG. \| last2 = Arber \| first2 = DA. \| last3 = Weiss \| first3 = LM. \| title = Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. \| journal = Am J Clin Pathol \| volume = 120 \| issue = 1 \| pages = 64-70 \| month = Jul \| year = 2003 \| doi = 10.1309/48KC-17WA-U69B-TBXQ \| PMID = 12866374 }}</ref>
			*MTAP -ve.<ref name=pmid34465883>{{cite journal \|authors=Dacic S \|title=Pleural mesothelioma classification-update and challenges \|journal=Mod Pathol \|volume=35 \|issue=Suppl 1 \|pages=51–56 \|date=January 2022 \|pmid=34465883 \|doi=10.1038/s41379-021-00895-7 \|url=}}</ref>
			**May not be sensitive and specific for peritoneal mesothelioma.{{fact}}

	==Molecular==		==Molecular==

Michael: /* Mesothelioma versus mesothelial hyperplasia */

2022-02-10T18:43:01Z

Mesothelioma versus mesothelial hyperplasia

← Older revision		Revision as of 18:43, 10 February 2022
Line 123:		Line 123:
	*EMA +ve ~100% (vs. ~10%).		*EMA +ve ~100% (vs. ~10%).
	*Desmin -ve ~5% (vs. ~85%).		*Desmin -ve ~5% (vs. ~85%).
	*GLUT1 +ve ~50% (vs. ~10%)		*GLUT1 +ve ~50% (vs. ~10%).
	*p53 +ve ~50% (vs. ~2%).		*p53 +ve ~50% (vs. ~2%).
	*BAP1 -ve.<ref name=pmid29085180>{{cite journal \|authors=Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S \|title=Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? \|journal=Dis Markers \|volume=2017 \|issue= \|pages=1310478 \|date=2017 \|pmid=29085180 \|pmc=5612603 \|doi=10.1155/2017/1310478 \|url=}}</ref>		*BAP1 -ve<ref name=pmid29085180>{{cite journal \|authors=Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S \|title=Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? \|journal=Dis Markers \|volume=2017 \|issue= \|pages=1310478 \|date=2017 \|pmid=29085180 \|pmc=5612603 \|doi=10.1155/2017/1310478 \|url=}}</ref> ~57%.<ref name=pmid26226841>{{cite journal \|authors=Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ \|title=Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology \|journal=Mod Pathol \|volume=28 \|issue=10 \|pages=1360–8 \|date=October 2015 \|pmid=26226841 \|pmc=4761613 \|doi=10.1038/modpathol.2015.87 \|url=}}</ref>

	Note:		Note:

Michael: /* Mesothelioma versus mesothelial hyperplasia */

2022-02-10T18:36:17Z

Mesothelioma versus mesothelial hyperplasia

← Older revision		Revision as of 18:36, 10 February 2022
Line 125:		Line 125:
	*GLUT1 +ve ~50% (vs. ~10%)		*GLUT1 +ve ~50% (vs. ~10%)
	*p53 +ve ~50% (vs. ~2%).		*p53 +ve ~50% (vs. ~2%).
			*BAP1 -ve.<ref name=pmid29085180>{{cite journal \|authors=Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S \|title=Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? \|journal=Dis Markers \|volume=2017 \|issue= \|pages=1310478 \|date=2017 \|pmid=29085180 \|pmc=5612603 \|doi=10.1155/2017/1310478 \|url=}}</ref>

	Note:		Note: